BL
SGMO

BFSG LLC’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

BFSG LLC’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,237
Closed -$1.26K – 706
2024
Q4 		$1.26K Hold
1,237
– – ﹤0.01% 625
2024
Q3 		$1.07K Sell
1,237
-2,429
-66% -$1.78K ﹤0.01% 602
2024
Q2 		$1.31K Hold
3,666
– – ﹤0.01% 586
2024
Q1 		$2.46K Buy
+3,666
New +$2.66K ﹤0.01% 582

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BFSG LLC's SGMO Position: Q1 2025 in Review

BFSG LLC sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2025, closing a stake of 1,237 shares — an estimated $1.26K sold.

BFSG LLC first reported a position in SGMO in Q1 2024 and held it in 4 quarters. The position peaked at $2.46K in Q1 2024. 122 funds tracked by Wall St. Rank hold SGMO as of Q1 2025.

  • BFSG LLC reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2025 after selling out during the quarter.
  • BFSG LLC sold 1,237 SANGAMO THERAPEUTICS INC shares in Q1 2025, an estimated $1.26K.
  • BFSG LLC first reported a position in SANGAMO THERAPEUTICS INC in Q1 2024 and held it in 4 quarters.
  • BFSG LLC's SANGAMO THERAPEUTICS INC position peaked at $2.46K in Q1 2024.
  • 122 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2025.

Based on BFSG LLC's 13F filing for Q1 2025, filed 18 Apr 2025.